Trial Summary
What is the purpose of this trial?The overall objectives of this study are to determine the effectiveness of ACE 2.0 model in early detection of advanced liver fibrosis, and to determine the acceptance and barriers for use of an AI-enabled algorithm for prediction of liver disease in primary care.
Eligibility Criteria
This trial is for adults who are getting an ECG test and whose doctors can order such tests. It's aimed at those in primary care settings, including physicians, nurse practitioners, and physician assistants who agree to participate. People with known advanced liver disease or a history of cirrhosis are not eligible.Treatment Details
The study is testing the ACE (AI-Cirrhosis-ECG) 2.0 model to see if it can effectively detect early signs of severe liver fibrosis using AI analysis of ECG results. The goal is also to assess how well this AI tool is accepted in a primary care environment.
2Treatment groups
Experimental Treatment
Active Control
Group I: Electrocardiogram AI GroupExperimental Treatment1 Intervention
The ACE (AI-Cirrhosis-ECG) 2.0 will be used to alert primary care providers to the likelihood of advanced liver disease with a recommendation for laboratory tests.
Group II: Usual Care GroupActive Control1 Intervention
Primary care providers will treat subject per standard of care
Find a clinic near you
Research locations nearbySelect from list below to view details:
Mayo Clinic MinnesotaRochester, MN
Loading ...
Who is running the clinical trial?
Mayo ClinicLead Sponsor